- CLINICAL TRIALS
- PARTNERS
- …
- CLINICAL TRIALS
- PARTNERS
- CLINICAL TRIALS
- PARTNERS
- …
- CLINICAL TRIALS
- PARTNERS
AmDTx is a first-in-class digital theragnostic platform.
Delivering customised, targeted curricula, AmDTx solves real world mental health issues through validated neurobehavioral interventions:
- Clinically validated patient programmes
- Market tested performance training
- Inspired wellness experiences
The you, You love.
Highlights
Personalised
AmDTx is personalised for every patient. Because more than anything else, the brain is what makes us all unique.
Measurements
AmDTx’s training is measured, promoting higher engagement and better outcomes through objective and benchmarked quantification of wellbeing. Scalable, easy to use, without a wearable.
Global
AmDTx is available world-wide in six languages (and counting). Administering indication-specific and client-specific content and features, from cancer survivorship and concussion to employee performance, anxiety and rehabilitation.
Certified as a DCB0129 Software as a Medical Device.
Access the corresponding Clinical Risk Management Processes below.
As a medical device, AmDTx contains some level of clinical risk. We describe these risks in detail through the following documentation.
An overview of Mobio Interactive's patient-facing mobile health platform.
Certifications
Mobio Interactive’s digital therapeutic platform “AmDTx” is CE MDD Class I, DCB0129, and ISO 27001 certified; GDPR-, HIPAA- and PHIPA-compliant; and undergoing certification for CE MDR Class IIa, ISO 13485, ISO 9000, and ISO 82304-2.
Validating the accuracy of our digital biomarkers and the efficacy of our digital theragnostic platform, AmDTx, Mobio has published 19 peer-reviewed papers to date from 17 completed clinical studies.
Effective and accessible healthcare for every human.